RLIP76 in Human Serum in Adults With Rheumatologic Diseases
It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.|
- The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera. [ Time Frame: three years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||September 2011|
|Estimated Primary Completion Date:||September 2011 (Final data collection date for primary outcome measure)|
This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00861159
|United States, Texas|
|University of North Texas Health Science Center|
|Fort Worth, Texas, United States, 76109|
|Principal Investigator:||Sanjay Awasthi, MD||University of North Texas Health Science Center|